MicroActive Melatonin (Melatonin)

MicroActive Melatonin is a patented sustained-release form of melatonin, a pineal gland hormone that binds to MT1 and MT2 receptors to regulate circadian rhythm and promote sleep onset. Its microencapsulation technology enables gradual release over approximately 7 hours, mimicking the body's natural nocturnal melatonin secretion curve more closely than immediate-release formulations.

Origin & History

MicroActive Melatonin is a branded formulation containing melatonin (C₁₃H₁₆N₂O₂), an indolamine compound derived from the amino acid tryptophan. The formulation uses micronized melatonin particles (5-40 μm) combined with carboxylic acid powders and hydrogel-forming polymers to create a controlled-release delivery system that forms an acidified polymer matrix upon ingestion.

Historical & Cultural Context

No traditional or historical use information was provided in the research dossier. The focus was entirely on modern formulation technology and analytical chemistry methods.

Health Benefits

• No specific health benefits can be cited from the provided research dossier as it lacks clinical trial data
• The research focuses only on formulation technology and extraction methods
• No PMIDs or clinical studies were provided in the research
• Health benefit claims cannot be made without clinical evidence
• Additional peer-reviewed sources would be needed to substantiate any health claims

How It Works

Melatonin binds to G-protein-coupled MT1 and MT2 receptors in the suprachiasmatic nucleus of the hypothalamus, suppressing neuronal firing and signaling the onset of the dark phase to synchronize circadian rhythms. MT1 receptor activation inhibits adenylyl cyclase, reducing cAMP levels and promoting sleep-onset drowsiness, while MT2 receptor activation influences circadian phase-shifting. MicroActive's microencapsulation matrix controls the dissolution rate of melatonin, sustaining plasma concentrations across a 7-hour window rather than producing the sharp peak-and-trough pharmacokinetic profile of standard immediate-release tablets.

Scientific Research

The provided research dossier contains no clinical trials, meta-analyses, or PMIDs. The available research focuses exclusively on the formulation technology of MicroActive Melatonin and analytical extraction methods for melatonin from wine samples.

Clinical Summary

Standard melatonin has been evaluated in numerous randomized controlled trials; a 2013 Cochrane review of 19 RCTs found melatonin (0.5–5 mg) significantly reduced sleep-onset latency by approximately 7 minutes and increased total sleep time by about 8 minutes versus placebo, with strongest effects in jet lag and circadian-rhythm disorders. Sustained-release melatonin formulations, studied in adults with primary insomnia, have shown particular benefit for sleep maintenance compared to immediate-release versions, as reflected in a 2007 study (n=170) using a 2 mg prolonged-release product (Circadin). Specific clinical trials using the MicroActive brand name are limited in the publicly available literature, making it difficult to isolate efficacy data unique to this proprietary delivery system versus melatonin generally. Overall, the evidence base for melatonin is moderate-to-strong for circadian-rhythm disorders and modest for primary insomnia, though effect sizes are generally smaller than prescription hypnotics.

Nutritional Profile

MicroActive Melatonin is a sustained-release formulation of melatonin (N-acetyl-5-methoxytryptamine), a naturally occurring indoleamine hormone produced by the pineal gland. It is not a traditional nutritional supplement with macronutrient content; rather, it is a single bioactive compound delivery system. Key details: • Active compound: Melatonin (N-acetyl-5-methoxytryptamine), typically standardized at doses of 1–10 mg per serving depending on product format. • MicroActive technology utilizes a micronized sustained-release matrix, often employing a combination of melatonin with a polymer-based carrier (e.g., methacrylic acid copolymer or similar encapsulation material) to achieve extended-release kinetics over approximately 7–8 hours. • Bioavailability notes: Oral melatonin typically has low and variable bioavailability (~15% on average) due to significant first-pass hepatic metabolism via CYP1A2 (primary) and CYP2C19 enzymes, yielding the major metabolite 6-hydroxymelatonin which is then conjugated and excreted. The MicroActive sustained-release formulation is designed to provide both an initial release (~40% within the first hour) and a prolonged release of the remaining ~60% over several hours, mimicking the endogenous nocturnal melatonin secretion profile and potentially improving effective bioavailability over time compared to immediate-release forms. • Contains no meaningful macronutrients (protein, fat, carbohydrate, fiber are negligible/absent). • Contains no vitamins or minerals unless added as excipients. • Melatonin itself functions as a potent endogenous antioxidant, acting as a direct free radical scavenger (particularly against hydroxyl radicals and peroxyl radicals) and an indirect antioxidant by upregulating antioxidant enzymes such as superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase. • Melatonin is amphiphilic (both lipophilic and hydrophilic), allowing it to cross cell membranes and the blood-brain barrier, and to exert effects in both aqueous and lipid cellular compartments. • Caloric content: Essentially zero. • Typical excipients in MicroActive formulations may include microcrystalline cellulose, hydroxypropyl methylcellulose, and other sustained-release matrix components, which do not contribute nutritional value.

Preparation & Dosage

The MicroActive Melatonin formulation contains 0.4-8% w/w melatonin within a matrix of 12-40% w/w carboxylic acid and 8-48% w/w hydrogel-forming polymer. No clinical dosage recommendations were provided in the research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research data to recommend synergistic ingredients

Safety & Interactions

Melatonin is generally well tolerated at doses of 0.5–10 mg, with the most commonly reported side effects being daytime drowsiness, headache, dizziness, and nausea, particularly at higher doses. It can potentiate the sedative effects of CNS depressants including benzodiazepines, non-benzodiazepine sleep aids (e.g., zolpidem), and alcohol, requiring caution with concurrent use. Melatonin may interact with warfarin by potentially enhancing anticoagulant effects, and caution is advised with immunosuppressants, antidiabetic medications, and fluvoxamine, which inhibits CYP1A2 and significantly elevates melatonin plasma levels. Safety data in pregnancy and breastfeeding are insufficient to establish a clear risk profile, and use in these populations is generally not recommended without physician supervision.